A low educational status was associated with longer delays before initiating treatment among relapsing-remitting MS patients ...

MinRes has copped a massive blow to its profit and won't pay a dividend as lithium, iron ore prices and additional capex hit.

Study finds that disease-modifying therapies for Alzheimer’s, lecanemab and donanemab, can extend independence in daily ...

Cybin (NYSE:CYBN – Free Report) had its price objective trimmed by HC Wainwright from $190.00 to $150.00 in a report published on Thursday,Benzinga reports. The brokerage currently has a buy rating on ...

The budding DIY psychedelics network is bypassing more traditional or trendy treatments, such as overseas organized retreats ...

We all come to adulthood with a certain amount of money baggage, so it's best to own those emotions and share them with your ...

Experts in Australia and New Zealand have published the first consensus guidelines for the care of adults with MS in those ...

DMT's take on the knitted shoe, which works well for relaxed rides and longer distances but lacks support for hard efforts ...

Aya will release its fourth quarter and full year 2024 financial and operational results before market open on March 28, 2025 and will host a conference call shortly afterwards. Details of the call ...

Algernon Pharmaceuticals Inc., a Canadian clinical stage pharmaceutical development company, announced that its wholly owned subsidiary, Algernon NeuroScience (AGN Neuro), has appointed Validcare as ...

Sarah Napthali lowers her voice over lunch when our conversation veers to the names of the drugs she used: LSD, MDMA, ...